Spondyloarthritis & psoriatic arthritis
Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database
Main finding · Overall cancerResult — go to the resultWeighted hazard ratio 0.86 95% CI 0.75–0.99Authors' conclusion
In this nationwide study, prolonged exposure to targeted therapies was not associated with an increased cancer risk. Exposure >6 months per year was associated with a lower cancer risk, mainly for hematological malignancies, whereas cumulative exposure over multiple years was not associated with cancer risk.
Study context
- Population
- Adults with spondyloarthritis (SpA) (incl. PsA, axial SpA, other subtypes) initiating a targeted therapy (TNFi, IL-17i, IL-12/23i, IL-23i, JAKi), January 2014 to September 2022, France; prior cancer, HIV infection or organ transplantation excludedmedian follow-up 5.0 years
- Participants
- 56,591 adults
- Exposure
- Targeted therapy exposure >6 months vs ≤6 months per year
- Outcome
- Incident cancer
Methodological detailsnationwide, French health insurance database, weighted Cox marginal structural models with inverse probability of treatment and censoring weights, post hoc sensitivity analysis
- Nationwide
- French health insurance database
- Weighted Cox marginal structural models with inverse probability of treatment and censoring weights
- Post hoc sensitivity analysis
Main finding
Overall cancer
Weighted hazard ratio
0.86
95% CI 0.75–0.99
>6 monthsvs ≤6 months
wHR 0.86 (95% CI 0.75–0.99)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | wHR (95% CI) | |
|---|---|---|
| Hematological malignancies (subgroup) | 0.65 (0.42–0.99) | |
| Solid cancers (subgroup) | 0.92 (0.79–1.07) | |
| 0.512Weighted hazard ratio (log scale) |
Cumulative exposure history (post hoc sensitivity analysis)
- Cumulative exposure history was not associated with cancer risk
- Post hoc
Original publication
Risk of Cancer According to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study From the French Health Insurance Database. Arthritis Rheumatol. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →